Heat Therapy for Peripheral Artery Disease

  • Research type

    Research Study

  • Full title

    A randomised controlled trial to evaluate heat therapy in the treatment of peripheral artery disease: clinical benefit and mechanisms of action

  • IRAS ID

    305780

  • Contact name

    Amy E Harwood

  • Contact email

    A.Harwood@mmu.ac.uk

  • Sponsor organisation

    Manchester Metropolitan University

  • Duration of Study in the UK

    3 years, 0 months, 0 days

  • Research summary

    When blood supply to the legs is restricted, this is a result of a serious common problem known as peripheral artery disease (PAD). People with this problem have severe pain in their legs when they walk, this is known as ‘intermittent claudication’. Often people with this problem are offered a supervised exercise programme. However, we know that many people cannot access or do not want to take part in exercise. Data from our own research, shows that heat therapy may be a potential solution. People may find that heat therapy is more enjoyable than exercise and provides similar health benefits. There is not much research into heat therapy in people with PAD. We have developed a new research study to look at whether heat therapy is safe and effective for people with PAD.

    We will undertake a randomised controlled trial (where people are allocated by chance to different conditions). We will compare bathing in hot water for 3 x per week to a control group who does nothing. To do this we need to determine whether this intervention is; 1) feasible for patients to undertake and 2) effective at improving the most important aspects of people’s disease symptoms. To assess this, we will make measurements using state-of-the-art cardiovascular and biochemical methods in people who have undergone this novel intervention and compare the results to patients who have not received any intervention.

  • REC name

    West Midlands - Black Country Research Ethics Committee

  • REC reference

    22/WM/0078

  • Date of REC Opinion

    21 Apr 2022

  • REC opinion

    Further Information Favourable Opinion